Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methsuximide SCHEMBL34852 | 0.77 | CYP19A1 (0.70) | CYP19A1ALDH1A1BACE1GRIN1GRIN2A | |
| Methsuximide SCHEMBL34853 | 0.77 | CYP19A1 (0.70) | CYP19A1ALDH1A1BACE1GRIN1GRIN2A | |
| SCHEMBL29116647 | 0.76 | CYP19A1 (0.50) | CYP19A1ALDH1A1BACE1MEN1KMT2A | |
| SCHEMBL20034768 | 0.74 | AR (0.35) | — | |
| SCHEMBL13684394 | 0.73 | CYP19A1 (0.44) | CYP19A1ALDH1A1BACE1MEN1KMT2A | |
| SCHEMBL14037658 | 0.73 | CYP19A1 (0.47) | CYP19A1BACE1CHRM2GRM2CYP2C19 | |
| SCHEMBL5347947 | 0.72 | CYP19A1 (0.40) | CYP19A1ALDH1A1BACE1MEN1KMT2A | |
| SCHEMBL24126788 | 0.71 | ELANE (0.56) | MEN1KMT2AGRM2CYP2C19NPSR1 | |
| SCHEMBL5334247 | 0.70 | ALDH1A1 (0.51) | CYP19A1ALDH1A1KMT2AMMP2MMP9 | |
| SCHEMBL8293499 | 0.70 | CYP19A1 (0.41) | CYP19A1ALDH1A1BACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP19A1 199/4885ALDH1A1 135/4885BACE1 1828/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | CYP19A1 244/4885ALDH1A1 153/4885BACE1 2524/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP19A1 199/4885ALDH1A1 135/4885BACE1 1828/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP19A1 199/4885ALDH1A1 135/4885BACE1 1828/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP19A1 199/4885ALDH1A1 135/4885BACE1 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.